BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Colorcon
Farmers Insurance
Dow
US Army
Novartis
Moodys
Merck
AstraZeneca
Boehringer Ingelheim

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,949,527

« Back to Dashboard

Which drugs does patent 6,949,527 protect, and when does it expire?

Patent 6,949,527 protects BRIDION and is included in one NDA.

This patent has thirty-nine patent family members in twenty-nine countries.
Summary for Patent: 6,949,527
Title: 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
Abstract:Disclosed is a 6-mercapto-cyclodextrin derivative having a general formula (I, ) wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C.sub.1-6) alkylene, optionally substituted with 1-3 OH groups, or (CH.sub.2).sub.o -phenylene-CH.sub.2).sub.p --; o and p are independently 0-4; X is COOH, CONHR.sub.3, NHCOR.sub.2, SO.sub.2 OH, PO(OH).sub.2, O(CH.sub.2 --CH.sub.2 --O).sub.q --H, OH or tetrazol-5-yl: R.sub.2 is H or (C.sub.1-3)alkyl; R.sub.2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof. The 6-mercaptocyclodextrin derivative is highly suitable for use in the reversal of drug-induced neuromuscular block.
Inventor(s): Zhang; Mingqiang (Montreal, CA), Palin; Ronald (Near Kilsyth, GB), Bennett; David Jonathan (Edinburgh, GB)
Assignee: Akzo Nobel N.V. (Arnhem, NL)
Application Number:10/603,355
Patent Claim Types:
see list of patent claims
Compound; Device; Use;

Drugs Protected by US Patent 6,949,527

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-002 Dec 15, 2015 RX Yes No ➤ Subscribe ➤ Subscribe REVERSAL OF NEUROMUSCLUAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE ➤ Subscribe
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-001 Dec 15, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe REVERSAL OF NEUROMUSCLUAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,949,527

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
99309558Nov 29, 1999

Non-Orange Book US Patents Family Members for Patent 6,949,527

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,670,340 6-Mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block ➤ Subscribe
RE44733 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,949,527

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland 203012 ➤ Subscribe
Poland 356097 ➤ Subscribe
Peru 09022001 ➤ Subscribe
New Zealand 518752 ➤ Subscribe
Norway 2010019 ➤ Subscribe
Norway 328790 ➤ Subscribe
Norway 20022522 ➤ Subscribe
Netherlands 300356 ➤ Subscribe
Mexico PA02004940 ➤ Subscribe
Luxembourg 91501 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
McKinsey
Moodys
Cipla
Queensland Health
Chubb
UBS
AstraZeneca
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot